These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 16078932)

  • 21. The leukodepletion of cellular blood products in the prevention of HLA-alloimmunization and refractoriness to allogeneic platelet transfusions.
    Heddle NM; Blajchman MA
    Blood; 1995 Feb; 85(3):603-6. PubMed ID: 7833464
    [No Abstract]   [Full Text] [Related]  

  • 22. How much residual plasma may cause TRALI?
    Win N; Chapman CE; Bowles KM; Green A; Bradley S; Edmondson D; Wallis JP
    Transfus Med; 2008 Oct; 18(5):276-80. PubMed ID: 18937733
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Management of patients refractory to platelet transfusion.
    Chockalingam P; Sacher RA
    J Infus Nurs; 2007; 30(4):220-5. PubMed ID: 17667077
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Post-transplant donor-specific antibody production and graft outcome in kidney transplantation: results of sixteen-year monitoring by flow cytometry.
    Piazza A; Poggi E; Ozzella G; Borrelli L; Scornajenghi A; Iaria G; Tisone G; Adorno D
    Clin Transpl; 2006; ():323-36. PubMed ID: 18365387
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tracking and characterisation of transfused platelets by two colour, whole blood flow cytometry.
    Hughes DL; Evans G; Metcalfe P; Goodall AH; Williamson LM
    Br J Haematol; 2005 Sep; 130(5):791-4. PubMed ID: 16115139
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New paradigms in the management of alloimmune refractoriness to platelet transfusions.
    Vassallo RR
    Curr Opin Hematol; 2007 Nov; 14(6):655-63. PubMed ID: 17898571
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A possible role for the production of multiple HLA antibodies in fatal platelet transfusion refractoriness after peripheral blood progenitor cell transplantation from the mother in a patient with relapsed leukemia.
    Nakazawa Y; Saito S; Hasegawa Y; Yanagisawa R; Sakashita K; Kamijo T; Miyazaki T; Sato S; Ikeda H; Ikebuchi K; Koike K
    Transfusion; 2007 Feb; 47(2):326-34. PubMed ID: 17302780
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transfusion related acute lung injury (TRALI) caused by red blood cell transfusion involving residual plasma anti-HLA antibodies: a report on two cases and general considerations.
    Odent-Malaure H; Quainon F; Ruyer-Dumontier P; Ducroz S; Verdier P; Voitellier E; Raynal MF; Fromont P; Muller JY; Rebibo D; Absi L; Garraud O
    Clin Dev Immunol; 2005 Dec; 12(4):243-8. PubMed ID: 16584109
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential use of IgG endopeptidase in the management of platelet refractoriness due to HLA alloimmunization.
    Burner JD; Goldfinger D
    Transfus Apher Sci; 2018 Jun; 57(3):409-410. PubMed ID: 29803623
    [No Abstract]   [Full Text] [Related]  

  • 30. Testing only donors with a prior history of pregnancy or transfusion is a logical and cost-effective transfusion-related acute lung injury prevention strategy.
    Powers A; Stowell CP; Dzik WH; Saidman SL; Lee H; Makar RS
    Transfusion; 2008 Dec; 48(12):2549-58. PubMed ID: 18717778
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Platelet transfusion and HLA immunisation.
    Sirchia G
    Vox Sang; 1986; 51(1):74. PubMed ID: 3739327
    [No Abstract]   [Full Text] [Related]  

  • 32. Utility of HLAMatchmaker and single-antigen HLA-antibody detection beads for identification of acceptable mismatches in highly sensitized patients awaiting kidney transplantation.
    Goodman RS; Taylor CJ; O'Rourke CM; Lynch A; Bradley JA; Key T
    Transplantation; 2006 May; 81(9):1331-6. PubMed ID: 16699463
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Platelet transfusion and isologous HLA].
    Amamiya Y; Hisamatsu J; Ito T; Baba M; Amaki T
    Rinsho Ketsueki; 1978 Oct; 19(10):1422-8. PubMed ID: 739602
    [No Abstract]   [Full Text] [Related]  

  • 34. Change of platelet activation markers using flow cytometry in patients with hematology/oncology disorders after transfusion.
    Lim YA; Cho SR; Lee WG; Park JS; Kim SW
    Platelets; 2008 Aug; 19(5):328-34. PubMed ID: 18791938
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Positive B-cell only flow cytometric crossmatch: implications for renal transplantation.
    Delgado JC; Eckels DD
    Exp Mol Pathol; 2008 Aug; 85(1):59-63. PubMed ID: 18499103
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of HLA alloimmunization by using leukocyte-depleted components.
    Andreu G; Dewailly J
    Curr Stud Hematol Blood Transfus; 1994; (60):29-40. PubMed ID: 8088168
    [No Abstract]   [Full Text] [Related]  

  • 37. Relevance of posttransplant flow cytometric T- and B-cell crossmatches in tacrolimus-treated renal transplant patients.
    Lenaers JI; Christiaans MH; Voorter CE; van Hooff HP; van den Berg-Loonen EM
    Transplantation; 2006 Nov; 82(9):1142-7. PubMed ID: 17102764
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical relevance of anti-HLA antibodies detected by flow-cytometry bead-based assays--single-center experience.
    Mihaylova A; Baltadjieva D; Boneva P; Ivanova M; Penkova K; Marinova D; Mihailova S; Paskalev E; Simeonov P; Naumova E
    Hum Immunol; 2006 Oct; 67(10):787-94. PubMed ID: 17055355
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Transfusion of cross-reactive HLA antigens is immunogenic.
    Kakaiya RM; Rosen D; Cable RG
    N Engl J Med; 1982 Jul; 307(4):254-5. PubMed ID: 7088083
    [No Abstract]   [Full Text] [Related]  

  • 40. Two cases of platelet transfusion refractoriness and one case of possible FNAIT caused by antibodies against CD36 in China.
    Xia W; Ye X; Xu X; Ding H; Liu J; Deng J; Chen Y; Shao Y; Wang J; Li H; Fu Y; Santoso S
    Transfus Med; 2014 Aug; 24(4):254-6. PubMed ID: 25124074
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.